MedTrace Logo

Study of FYU-981 in Hyperuricemia With or Without Gout

NCT03006445 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2018-12-06

No results posted yet for this study

Summary

The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981 administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the method of multicenter, open label and ascending dose regimen.

Conditions

  • Hyperuricemia With or Without Gout

Interventions

DRUG

FYU-981

Sponsors & Collaborators

  • Mochida Pharmaceutical Company, Ltd.

    collaborator INDUSTRY

  • Fuji Yakuhin Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-08-23
Completion
2018-10-24

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006445 on ClinicalTrials.gov